ZEALAND PHARMA A/S Inactive Instrument
Zealand Pharma A/S Stock Nasdaq
Equities
ZEAL
US98920Y3045
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 441M 64.13M | Sales 2025 * | 1.02B 148M | Capitalization | 37.38B 5.44B |
|---|---|---|---|---|---|
| Net income 2024 * | -653M -95M | Net income 2025 * | -611M -88.89M | EV / Sales 2024 * | 79.4 x |
| Net cash position 2024 * | 2.37B 345M | Net cash position 2025 * | 2.44B 355M | EV / Sales 2025 * | 34.3 x |
| P/E ratio 2024 * |
-60
x | P/E ratio 2025 * |
-63.2
x | Employees | 270 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 09-12-31 | |
| Director of Finance/CFO | - | 22-10-31 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-04-03 |
| Chairman | 69 | 14-12-31 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18-04-18 |
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-08-15
- Q2 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +8.33% | 115B | |
| +12.99% | 107B | |
| -13.62% | 22.31B | |
| -3.99% | 21.6B | |
| -5.79% | 18.23B | |
| -39.93% | 17.62B | |
| +7.46% | 14.26B | |
| +33.48% | 12.37B | |
| -28.25% | 8.28B |
